Coya Therapeutics' (COYA) "Buy" Rating Reiterated at Roth Capital

Key Points

• Roth Capital reiterated its “Buy” rating on Coya Therapeutics and maintained a $12 price target, implying approximately 143.7% upside from the stock’s $4.92 price.
• Analyst sentiment is generally positive, with six Buy ratings and one Sell rating; MarketBeat lists a “Moderate Buy” consensus and an average target price of $15.33.
• Coya reported a quarterly loss of $0.28 per share, beating estimates by $0.07, while revenue of $0.24 million exceeded expectations; however, the company continues to post substantial negative margins and return on equity.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Roth Capital in a report released on Monday,Benzinga reports. They currently have a $12.00 price objective on the stock. Roth Capital's price target would indicate a potential upside of 143.70% from the company's current price.

A number of other brokerages also recently weighed in on COYA. Wall Street Zen downgraded shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Coya Therapeutics in a research report on Friday, July 17th. HC Wainwright restated a "buy" rating on shares of Coya Therapeutics in a research note on Monday. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Wednesday, August 12th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.33.

Coya Therapeutics Stock Performance

NASDAQ COYA traded up $0.05 during trading hours on Monday, hitting $4.92. 55,156 shares of the company traded hands, compared to its average volume of 188,206. The business's 50-day moving average is $4.90 and its 200-day moving average is $4.67. The stock has a market capitalization of $115.52 million, a price-to-earnings ratio of -4.60 and a beta of 0.61. Coya Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.75.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Analysts predict that Coya Therapeutics will post -1.44 EPS for the current year.

Institutional Trading of Coya Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Long Corridor Asset Management Ltd acquired a new stake in Coya Therapeutics during the second quarter worth approximately $227,000. Cetera Investment Advisers increased its stake in shares of Coya Therapeutics by 36.4% during the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company's stock worth $118,000 after purchasing an additional 8,000 shares during the period. Occudo Quantitative Strategies LP bought a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $66,000. Millennium Management LLC bought a new stake in Coya Therapeutics in the 4th quarter valued at $121,000. Finally, CIBC Private Wealth Group LLC bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $47,000. Institutional investors own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source